查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971771

感染疾病治疗市场分析及预测（至2035年）：依类型、产品、服务、技术、应用、最终使用者、设备、流程及解决方案划分

Infectious Disease Therapeutics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Process, Solutions
出版日期: | 出版商: Global Insight Services | 英文 425 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计感染疾病治疗市场规模将从2024年的1,267亿美元成长到2034年的1,930亿美元，复合年增长率约为4.3%。该市场涵盖病毒、细菌、真菌和寄生虫性行为感染的治疗，包括抗生素、抗病毒药物、抗真菌药物和疫苗，并专注于新药研发和抗抗药性措施。感染疾病上升、研发投入增加以及生物技术的进步正在推动市场成长。公众意识的提高、政府主导的各项倡议，以及对个人化医疗和快速诊断的重视（旨在提高治疗效果和改善患者预后），进一步刺激了市场需求。

受药物研发进展和感染疾病上升的推动，感染疾病治疗市场正经历强劲成长。其中，抗病毒疗法特别突出，爱滋病和肝炎治疗领域的创新是主要驱动力。抗菌疗法紧随其后，重点在于对抗抗药性细菌。疫苗是关键成长领域，针对新兴感染疾病的新型疫苗备受关注。单株抗体正成为极具发展潜力的细分市场，提供副作用较少的标靶治疗选择。抗真菌药物真菌疗法也呈现成长势头，旨在应对免疫力缺乏患者中真菌感染疾病日益增多的问题。新型药物递送系统的研发正在提高治疗药物的疗效和可近性。生物製药和生物相似药透过提供经济有效的替代方案，为市场扩张做出贡献。人工智慧在药物研发和个人化医疗的应用有望变革治疗方法，优化治疗效果，并推动未来的成长。

市场区隔
类型 抗菌剂、抗病毒药物、抗真菌剂、抗寄生虫剂、疫苗、免疫调节剂、生物製药、小分子化合物
产品 口服药物、注射药物、外用製剂、吸入药物、静脉注射药物、经皮贴片
服务 临床试验、法规遵循、契约製造、药物研发
科技 基因组学、蛋白质组学、代谢体学、奈米技术、CRISPR
目的 爱滋病毒、肝炎、流感、结核病、疟疾、新冠肺炎、医院感染
最终用户 医院、诊所、研究机构、製药公司、生技公司
装置 诊断设备、输液设备、监测设备
过程 药物发现、非临床试验、临床试验、核准、商业化
解决方案 感染控制、合理使用抗生素方案、快速诊断

市场概况：

感染疾病治疗市场的特征是市场份额、定价策略和新产品上市之间存在着动态的相互作用。製药公司正利用先进技术推出创新疗法，以提高疗效并改善患者预后。医疗政策和报销框架加剧了定价策略的竞争。研发投入的增加以及致力于满足未被满足的医疗需求的努力，推动了市场上新产品的涌现。旨在拓展市场和强化产品系列的策略联盟和併购进一步塑造了这个不断变化的市场格局。传染病治疗市场的竞争异常激烈，主要企业专注于透过创新和策略联盟实现差异化。监管影响显着，严格的核准流程影响产品上市的速度。北美和欧洲凭藉其强大的感染疾病基础设施和有利的法规环境。亚太地区正崛起为一个高盈利市场，这主要得益于投资的增加和感染疾病的蔓延。生物技术和个人化医疗的进步创造了充满希望的前景，市场正蓄势待发，成长势头强劲。

主要趋势和驱动因素：

感染疾病治疗市场正经历强劲成长，这主要得益于几个关键趋势和驱动因素。其中一个显着趋势是，为应对新出现的感染疾病和流行病，研发活动激增，旨在发现新的疗法和疫苗。生物技术和基因组学的进步正在加速个人化医疗的发展，提供更有针对性和更有效的治疗方法。另一个趋势是製药公司与研究机构之间合作的加强，这加速了药物发现过程，并促进了创新治疗方法的开发。世界各国政府对医疗基础设施的大量投资进一步推动了市场成长。法规结构也不断完善，以加速新药核准，确保患者及时获得救命疗法。市场驱动因素包括需要有效治疗方案的感染疾病在全球范围内的不断蔓延。人们意识的提高和诊断能力的增强也推动了对先进治疗方法的需求。此外，发展中地区医疗服务覆盖范围的扩大也创造了新的机会。能够妥善应对监管环境并投资于前沿研发的公司，将更有利于利用这些趋势和驱动因素，确保市场可持续成长。

压制与挑战：

感染疾病治疗市场面临许多重大限制与挑战。其中一个突出障碍是药物研发高成本，这对许多公司，尤其是中小企业而言，构成了沉重的财务负担。这种财务负担往往限制了研发活动，减缓了创新步伐。此外，严格的监管要求会延误核准流程，进一步加重财务负担，并延长新治疗方法的上市时间。抗药性病原体的出现也使治疗通讯协定复杂化，需要持续的研究和调整。此外，医疗基础设施的差异限制了药物的分发和供应，使得确保不同地区患者公平获得治疗成为一项持续的挑战。最后，诸如大流行病等公共卫生突发事件会分散资源和注意力，使其他感染疾病的研发工作受到影响。这些因素共同阻碍了市场成长和药物可近性，需要製定策略解决方案来克服这些挑战。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 抗菌剂
    • 抗病毒药物
    • 抗真菌剂
    • 抗寄生虫药物
    • 疫苗
    • 免疫调节剂
    • 生物製药
    • 低分子化合物
  • 市场规模及预测：依产品划分
    • 口服药物
    • 注射药物
    • 外用製剂
    • 吸入製剂
    • 静脉注射药物
    • 经皮吸收贴剂
  • 市场规模及预测：依服务划分
    • 临床试验
    • 监理合规
    • 契约製造
    • 药物研发
  • 市场规模及预测：依技术划分
    • 基因组学
    • 蛋白质体学
    • 代谢体学
    • 奈米科技
    • CRISPR
  • 市场规模及预测：依应用领域划分
    • HIV
    • 肝炎
    • 流感
    • 结核
    • 疟疾
    • COVID-19
    • 院内感染
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究机构
    • 製药公司
    • 生技公司
  • 市场规模及预测：依设备划分
    • 诊断设备
    • 药物输送装置
    • 监控设备
  • 市场规模及预测：依製程划分
    • 药物发现
    • 非临床试验
    • 临床试验
    • 核准
    • 商业化
  • 市场规模及预测：按解决方案划分
    • 感染控制
    • 合理使用抗生素
    • 快速诊断

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Gilead Sciences
  • Regeneron Pharmaceuticals
  • BioCryst Pharmaceuticals
  • Arcturus Therapeutics
  • Vir Biotechnology
  • Novavax
  • Spero Therapeutics
  • Atea Pharmaceuticals
  • Vaxart
  • Dynavax Technologies
  • Inovio Pharmaceuticals
  • Iovance Biotherapeutics
  • Moderna
  • Valneva
  • CureVac
  • Bavarian Nordic
  • Sorrento Therapeutics
  • Altimmune
  • Siga Technologies
  • Emergent BioSolutions

第九章 关于我们

简介目录
Product Code: GIS33151

Infectious Disease Therapeutics Market is anticipated to expand from $126.7 billion in 2024 to $193.0 billion by 2034, growing at a CAGR of approximately 4.3%. The Infectious Disease Therapeutics Market encompasses treatments targeting viral, bacterial, fungal, and parasitic infections. It includes antibiotics, antivirals, antifungals, and vaccines, emphasizing novel drug development and resistance management. The market is propelled by rising infection rates, increased R&D investments, and advancements in biotechnology. Growing awareness and government initiatives further fuel demand, with a focus on personalized medicine and rapid diagnostics to enhance treatment efficacy and patient outcomes.

The Infectious Disease Therapeutics Market is experiencing robust growth, fueled by advancements in drug development and increasing prevalence of infectious diseases. The antiviral therapeutics segment leads in performance, particularly driven by innovations in HIV and hepatitis treatments. Antibacterial therapeutics follow closely, with a focus on combating antibiotic-resistant strains. Vaccines represent a significant growth area, with novel vaccines for emerging diseases gaining attention. Monoclonal antibodies are emerging as a promising sub-segment, offering targeted treatment options with fewer side effects. The antifungal segment is also gaining momentum, addressing rising incidences of fungal infections in immunocompromised patients. Research and development in novel drug delivery systems are enhancing the efficacy and accessibility of therapeutics. Biologics and biosimilars are contributing to market expansion, providing cost-effective alternatives. The integration of artificial intelligence in drug discovery and personalized medicine is poised to transform therapeutic approaches, optimizing treatment outcomes and driving future growth.

Market Segmentation
TypeAntibacterials, Antivirals, Antifungals, Antiparasitics, Vaccines, Immune Modulators, Biologics, Small Molecules
ProductOral Drugs, Injectable Drugs, Topical Formulations, Inhalation Formulations, Intravenous Drugs, Transdermal Patches
ServicesClinical Trials, Regulatory Compliance, Custom Manufacturing, Drug Development
TechnologyGenomics, Proteomics, Metabolomics, Nanotechnology, CRISPR
ApplicationHIV, Hepatitis, Influenza, Tuberculosis, Malaria, COVID-19, Hospital Acquired Infections
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Firms
DeviceDiagnostic Devices, Drug Delivery Devices, Monitoring Devices
ProcessDiscovery, Preclinical Trials, Clinical Trials, Approval, Commercialization
SolutionsInfection Control, Antimicrobial Stewardship, Rapid Diagnostics

Market Snapshot:

The Infectious Disease Therapeutics Market is characterized by a dynamic interplay of market share, pricing strategies, and new product launches. Pharmaceutical companies are leveraging advanced technologies to introduce innovative therapeutics, enhancing treatment efficacy and patient outcomes. Pricing strategies remain competitive, influenced by healthcare policies and reimbursement frameworks. The market is witnessing a surge in product launches, driven by increased R&D investments and a focus on addressing unmet medical needs. This evolving landscape is further shaped by strategic partnerships and mergers aimed at expanding market reach and enhancing product portfolios. Competition in the Infectious Disease Therapeutics Market is intense, with key players focusing on differentiation through innovation and strategic alliances. Regulatory influences are significant, with stringent approval processes impacting the speed of product launches. North America and Europe dominate the market, driven by robust healthcare infrastructures and supportive regulatory environments. Asia-Pacific is emerging as a lucrative region, fueled by growing investments and increasing prevalence of infectious diseases. The market is poised for growth, with advancements in biotechnology and personalized medicine offering promising prospects.

Geographical Overview:

The Infectious Disease Therapeutics Market is witnessing notable growth across various regions, each exhibiting unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and significant R&D investments. The presence of key pharmaceutical companies further propels the market. Europe follows, with robust government initiatives and funding for infectious disease research bolstering market growth. Asia Pacific is experiencing rapid expansion, fueled by increasing healthcare expenditure and a rising prevalence of infectious diseases. Emerging economies like India and China are at the forefront, with substantial investments in healthcare innovation. Latin America presents new growth pockets, with improving healthcare systems and rising awareness about infectious disease treatment. The Middle East & Africa are also gaining traction, recognizing the critical need for effective therapeutics in combating infectious diseases. These regions are seeing increased collaborations with global pharmaceutical firms, which enhances their market potential and fosters innovation in therapeutics.

Key Trends and Drivers:

The Infectious Disease Therapeutics Market is experiencing robust growth, propelled by several key trends and drivers. One significant trend is the surge in research and development activities aimed at discovering novel therapeutics and vaccines. This is fueled by the urgent need to combat emerging infectious diseases and pandemics. Advances in biotechnology and genomics are facilitating the development of personalized medicine, offering targeted and effective treatments. Another trend is the increasing collaboration between pharmaceutical companies and research institutions. This collaboration accelerates the drug discovery process and enhances the development of innovative therapies. Governments worldwide are investing heavily in healthcare infrastructure, further boosting market growth. Regulatory frameworks are evolving to expedite the approval of new drugs, ensuring timely access to life-saving treatments. Market drivers include the rising prevalence of infectious diseases globally, necessitating effective therapeutic solutions. Growing awareness and improved diagnostic capabilities are also driving demand for advanced treatments. Additionally, the expansion of healthcare access in developing regions is creating new opportunities. Companies that can navigate regulatory landscapes and invest in cutting-edge research are poised to capitalize on these trends and drivers, ensuring sustained market growth.

Restraints and Challenges:

The infectious disease therapeutics market is confronted with several significant restraints and challenges. A prominent hurdle is the high cost of drug development, which poses financial barriers for many companies, particularly smaller firms. This financial burden often results in limited research and development activities, slowing innovation. Moreover, stringent regulatory requirements can delay the approval process, adding further financial strain and extending time-to-market for new therapies. The emergence of drug-resistant strains of pathogens also complicates treatment protocols, necessitating continuous research and adaptation. Additionally, there is a persistent challenge in ensuring equitable access to therapies across different regions, as disparities in healthcare infrastructure can limit distribution and availability. Lastly, public health emergencies, such as pandemics, can redirect resources and attention away from other infectious diseases, impacting ongoing research and development efforts. These factors collectively impede the market's growth and accessibility, requiring strategic solutions to overcome them.

Key Players:

Gilead Sciences, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, Arcturus Therapeutics, Vir Biotechnology, Novavax, Spero Therapeutics, Atea Pharmaceuticals, Vaxart, Dynavax Technologies, Inovio Pharmaceuticals, Iovance Biotherapeutics, Moderna, Valneva, CureVac, Bavarian Nordic, Sorrento Therapeutics, Altimmune, Siga Technologies, Emergent BioSolutions

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Antibacterials
    • 4.1.2 Antivirals
    • 4.1.3 Antifungals
    • 4.1.4 Antiparasitics
    • 4.1.5 Vaccines
    • 4.1.6 Immune Modulators
    • 4.1.7 Biologics
    • 4.1.8 Small Molecules
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Oral Drugs
    • 4.2.2 Injectable Drugs
    • 4.2.3 Topical Formulations
    • 4.2.4 Inhalation Formulations
    • 4.2.5 Intravenous Drugs
    • 4.2.6 Transdermal Patches
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Clinical Trials
    • 4.3.2 Regulatory Compliance
    • 4.3.3 Custom Manufacturing
    • 4.3.4 Drug Development
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Genomics
    • 4.4.2 Proteomics
    • 4.4.3 Metabolomics
    • 4.4.4 Nanotechnology
    • 4.4.5 CRISPR
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 HIV
    • 4.5.2 Hepatitis
    • 4.5.3 Influenza
    • 4.5.4 Tuberculosis
    • 4.5.5 Malaria
    • 4.5.6 COVID-19
    • 4.5.7 Hospital Acquired Infections
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Biotechnology Firms
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Diagnostic Devices
    • 4.7.2 Drug Delivery Devices
    • 4.7.3 Monitoring Devices
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical Trials
    • 4.8.3 Clinical Trials
    • 4.8.4 Approval
    • 4.8.5 Commercialization
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Infection Control
    • 4.9.2 Antimicrobial Stewardship
    • 4.9.3 Rapid Diagnostics

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Gilead Sciences
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Regeneron Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 BioCryst Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Arcturus Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vir Biotechnology
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Novavax
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Spero Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Atea Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Vaxart
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Dynavax Technologies
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Inovio Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Iovance Biotherapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Moderna
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Valneva
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 CureVac
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bavarian Nordic
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sorrento Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Altimmune
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Siga Technologies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Emergent BioSolutions
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us